Open AccessSelective Arterial Embolization for the Treatment of Sacral and Pelvic Giant Cell Tumor: A Systematic Review
Author(s) -
He Shaohui,
Xu Wei,
Sun Zhengwang,
Liu Weibo,
Liu Yujie,
Wei Haifeng,
Xiao Jianru
Publication year - 2017
Publication title -
orthopaedic surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.666
H-Index - 23
eISSN - 1757-7861
pISSN - 1757-7853
DOI - 10.1111/os.12336
Subject(s) - medicine , embolization , surgery , arterial embolization , inclusion and exclusion criteria , giant cell tumor of bone , radiation therapy , radiology , giant cell , alternative medicine , pathology
Giant cell tumor of the bone ( GCTB ) is a locally aggressive tumor with a certain distant metastatic rate. For sacral GCT ( SGCT ) and pelvic GCT ( PGCT ), surgery has its limitations, especially for unresectable or recurrent tumors. Selective arterial embolization ( SAE ) is reported to be an option for treatment in several cases, but there are few systematic reviews on the effects of SAE on SGCT and/or PGCT . Medline and Embase databases were searched for eligible English articles. Inclusion and exclusion criteria were conducted before searching. All the clinical factors were measured by SPSS software, with P ‐values ≤0.05 considered statistically significant. A total of 9 articles were retrieved, including 44 patients receiving SAE ranging from 1 to 10 times. During the mean follow‐up period of 85.8 months, the radiographic response rate was 81.8%, with a local control and overall survival rate of 75% and 81.8%, respectively. No bowel, bladder, or sexual dysfunction was observed. Three patients developed distant metastases and finally died. Patients with primary tumors tended to have better prognosis than those with recurrence ( P = 0.039). The favorable outcomes of SAE suggest that it may be an alternative treatment for SGCT and PGCT patients for whom surgery is not appropriate.